,user_input,reference_contexts,reference,persona_name,query_style,query_length,synthesizer_name
0,Can you tell me what Sym004 is and how it is used in the clinical trial for patients with metastatic colorectal cancer?,"[""CLINICAL TRIAL PROTOCOL\nTrial Title:\nAn Open-label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer Progressing after First-Line Therapy\nShort Title:\nSym004 in Combination with FOLFIRI in Metastatic Colorectal Cancer Patients\nSponsor:\nSymphogen A/S\nSponsor's Medical Expert:\nCoordinating Investigator:\nTrial ID:\nSym004-09\nTrial Phase:\nPhase 1b/2a\nEudraCT number:\n2015-003047-19\nIND Number:\n105953\nProtocol Version/Date:\n4.0 / 22-Feb-2017 (Amendment 3)\nPrevious Protocol Versions/Dates:\n3.0 / 05-Aug-2016 (Amendment 2)\n2.0 / 09-Nov-2015 (Amendment 1)\n1.0 / 26-Aug-2015\nList of Responsible Person/ Contact Listing\nLists of Investigators responsible for conducting the trial, medically qualified physicians responsible for all trial site related medical decisions (if other than the Investigators), Monitors, clinical laboratories and other medical and/or\ntechnical departments and/or institutions involved in the trial are provided as separate documents.""]","Sym004 is being investigated in a clinical trial that looks at different doses of it in combination with FOLFIRI for patients who have metastatic colorectal cancer that is progressing after first-line therapy. This trial is an open-label, multi-center Phase 1b/2a study sponsored by Symphogen A/S.",Patient Recruitment Specialist,MISSPELLED,LONG,single_hop_specific_query_synthesizer
1,What is the GCP Stetement in the clinical trial protocol?,"['CLINICAL TRIAL PROTOCOL\nGCP Statement: The trial will be conducted in compliance with this Clinical Trial Protocol, ICH E6 GCP (1) and applicable regulations.\nThis confidential document is the property of Symphogen A/S. No unpublished information contained herein may be passed on, reproduced, published or used without prior written approval from Symphogen A/S. Access to this document must be restricted to relevant parties.']","The GCP Statement in the clinical trial protocol indicates that the trial will be conducted in compliance with the Clinical Trial Protocol, ICH E6 GCP (1), and applicable regulations.",Clinical Research Associate (CRA),MISSPELLED,MEDIUM,single_hop_specific_query_synthesizer
2,Can you provide an overview of the approval process for a Clinical Trial Protocol as indicated by the sponsor's statement?,['Sponsor\nI hereby approve the Clinical Trial Protocol as suitable and appropriate for use.\nSymphogen A/S\nSymphogen A/S\nSymphogen A/S\nSymphogen A/S'],"The approval process for a Clinical Trial Protocol involves the sponsor's formal endorsement, as evidenced by the statement 'I hereby approve the Clinical Trial Protocol as suitable and appropriate for use.' This indicates that the sponsor, in this case, Symphogen A/S, has reviewed the protocol and deemed it compliant with necessary standards for conducting the clinical trial.",Clinical Research Associate (CRA),PERFECT_GRAMMAR,LONG,single_hop_specific_query_synthesizer
3,What is the responsibilty of the principal investigator in a clinicl trial?,"[""Signature Page Principal Investigator\nI, the undersigned, am responsible for the conduct of the trial at this site and agree;\n- \uf0b7 To assume responsibility for the proper conduct of the clinical trial at this Investigational Site\n- \uf0b7 Not to implement any changes to the Clinical Trial Protocol without agreement from the Sponsor and prior review and written approval from the Ethics Committee, except where necessary to eliminate an immediate hazard to the patient\n- \uf0b7 That I am aware of, and will comply with 'Good Clinical Practice' (ICH GCP) (CPMP/ICH/135/95) and all applicable regulatory requirements\n- \uf0b7 That all site staff to which I have delegated tasks for this clinical trial, are adequately informed about the investigational product(s) and of their trial-related duties and functions as described in the Clinical Trial Protocol\n________________________________\n____________________\nSignature\nDate of Signature\nName:\nAcademic degree:\nFunction:\nInstitution:""]","The principal investigator is responsible for the proper conduct of the clinical trial at the site. They must not implement any changes to the Clinical Trial Protocol without agreement from the Sponsor and prior review and written approval from the Ethics Committee, except when necessary to eliminate an immediate hazard to the patient. They also need to ensure that all site staff delegated tasks for the clinical trial are adequately informed about the investigational product(s) and their trial-related duties as described in the Clinical Trial Protocol.",Patient Recruitment Specialist,MISSPELLED,LONG,single_hop_specific_query_synthesizer
4,What section of the document contains the definitions of terms?,"['TABLE OF CONTENTS\n1, 1 = LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS......................... 1, 2 = 11. 2, 1 = SYNOPSIS.............................................................................................................. 2, 2 = 14. 3, 1 = BACKGROUND AND RATIONALE................................................................... 3, 2 = 19. 3.1, 1 = Disease']",The definitions of terms are found in the section titled 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS' as indicated in the Table of Contents.,Clinical Research Associate (CRA),WEB_SEARCH_LIKE,SHORT,single_hop_specific_query_synthesizer
5,Can you provide details regarding the significance of Version 4.0 in the context of the Schedule of Events for Trial ID: Sym004-09?,"['TABLE OF CONTENTS\n5.3, Trial ID: Sym004-09 = Schedule of Events.................................................................................................. 5.3, Version 4.0 = 31. 5.3.1, Trial ID: Sym004-09 =']","Version 4.0 is referenced in the context of the Schedule of Events for Trial ID: Sym004-09, indicating a specific iteration of the trial documentation that outlines the events and procedures to be followed during the trial. This version is crucial for ensuring that all stakeholders are aligned with the latest updates and requirements as stipulated in the trial protocol.",Clinical Research Associate (CRA),PERFECT_GRAMMAR,LONG,single_hop_specific_query_synthesizer
6,What does the treatment of skin toxicity involve in the context of clinical trials?,"['TABLE OF CONTENTS\n7.2.3.2, Symphogen Trial ID: Sym004-09 = Prophylactic Treatment for Gastrointestinal Toxicities .......................................... 7.2.3.2, Clinical Trial Protocol Version 4.0 = 53. 7.2.3.3, Symphogen Trial ID: Sym004-09 = Prophylactic Treatment for Skin Toxicity............................................................... 7.2.3.3, Clinical Trial Protocol Version 4.0 = 54. 7.2.4, Symphogen Trial ID: Sym004-09 = Treatment of Skin Toxicity']","The treatment of skin toxicity is addressed in the Symphogen Trial ID: Sym004-09, as outlined in the clinical trial protocol.",Patient Recruitment Specialist,PERFECT_GRAMMAR,MEDIUM,single_hop_specific_query_synthesizer
7,"What are the key sections related to Trial ID: Sym004-09 in the provided context, and what do they cover?","['TABLE OF CONTENTS\n8.8, Trial ID: Sym004-09 = Follow-up Assessments........................................................................................... 8.8, Version 4.0 = 73. 8.9, Trial ID: Sym004-09 = Appropriateness of Measurements.......................................................................... 8.9, Version 4.0 = 73. 9, Trial ID: Sym004-09 = ADVERSE']","The key sections related to Trial ID: Sym004-09 in the provided context include: 8.8, which covers Follow-up Assessments, and 8.9, which addresses the Appropriateness of Measurements. Both sections are part of Version 4.0 and are referenced on page 73. Additionally, section 9 pertains to ADVERSE events related to Trial ID: Sym004-09.",Clinical Research Associate (CRA),WEB_SEARCH_LIKE,LONG,single_hop_specific_query_synthesizer
8,What is the role of the Independent Ethics Committee in clinical trials?,"['TABLE OF CONTENTS\n11.1, Symphogen Trial ID: Sym004-09 = Independent Ethics Committee or Institutional Review Board............................... 11.1, Clinical Trial Protocol Version 4.0 = 88. 11.2, Symphogen Trial ID: Sym004-09 = Patient Information and Informed Consent............................................................. 11.2, Clinical Trial Protocol Version 4.0 = 88. 11.3, Symphogen Trial ID: Sym004-09 = Compliance Reference']","The Independent Ethics Committee, also known as the Institutional Review Board, is responsible for overseeing the ethical aspects of clinical trials, ensuring that the rights and welfare of participants are protected.",Patient Recruitment Specialist,PERFECT_GRAMMAR,SHORT,single_hop_specific_query_synthesizer
9,What section of the document addresses Infusion-Related Reactions Management?,"['TABLE OF CONTENTS\nTable 2, 1 = Flow Chart - Schedule of Assessments .................................................................. Table 2, 2 = 35. Table 3, 1 = Description of Investigational Medicinal Product/Sym004.................................... Table 3, 2 = 44. Table 4, 1 = Infusion Rate for Administration of Sym004.......................................................... Table 4, 2 = 47. Table 5, 1 = Infusion-Related Reactions Management']","Infusion-Related Reactions Management is addressed in Table 5, 1 of the document.",Clinical Research Associate (CRA),PERFECT_GRAMMAR,MEDIUM,single_hop_specific_query_synthesizer